Laparoscopic splenic hilum lymph node dissection for advanced proximal gastric cancer: A modified approach for pancreas- and spleen-preserving total gastrectomy

Ting-Yu Mou, Yan-Feng Hu, Jiang Yu, Hao Liu, Ya-Nan Wang, Guo-Xin Li

Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China

Author contributions: Mou TY and Hu YF contributed equally to this work in the design of the study and preparation of the manuscript and should be both considered as co-first authors; Yu J, Wang YN and Li GX performed the surgeries; Liu H analyzed the data.

Supported by The National High Technology Research and Development Program of China (863 Program) issued by the Ministry of Science and Technology of China, No. 2012AA021103; and the Ministry of Health of China, No. W2011WAI44

Correspondence to: Guo-Xin Li, MD, Department of General Surgery, Nanfang Hospital, Southern Medical University, No. 1838, North Guangzhou Avenue, Guangzhou 510515, Guangdong Province, China. gzliguoxin@163.com

Telephone: +86-20-61641682 Fax: +86-20-61641683

Received: April 2, 2013 Revised: May 31, 2013 Accepted: June 18, 2013

Abstract

AIM: To investigate the feasibility and optimal approach for laparoscopic pancreas- and spleen-preserving splenic hilum lymph node dissection in advanced proximal gastric cancer.

METHODS: Between August 2009 and August 2012, 12 patients with advanced proximal gastric cancer treated in Nanfang Hospital, Southern Medical University, Guangzhou, China were enrolled and subsequently underwent laparoscopic total gastrectomy with pancreas- and spleen-preserving splenic hilum lymph node (LN) dissection. The clinicopathological characteristics, surgical outcomes, postoperative course and follow-up data of these patients were retrospectively collected and analyzed in the study.

RESULTS: Based on our anatomical understanding of peripancreatic structures, we combined the characteristics of laparoscopic surgery and developed a modified approach (combined supra- and infra-pancreatic approaches) for laparoscopic pancreas- and spleen-preserving splenic hilum LN dissection. Surgery was completed in all 12 patients laparoscopically without conversion. Only one patient experienced intraoperative bleeding when dissecting LNs along the splenic artery and was handled with laparoscopic hemostasis. The mean operating time was 268.4 min and mean number of retrieved splenic hilum LNs was 4.8. One patient had splenic hilum LN metastasis (8.3%). Neither postoperative morbidity nor mortality was observed. Peritoneal metastasis occurred in one patient and none of the other patients died or experienced recurrent disease during the follow-up period.

CONCLUSION: Laparoscopic total gastrectomy with pancreas- and spleen-preserving splenic hilum LN dissection using the modified approach for advanced proximal gastric cancer could be safely achieved.

© 2013 Baishideng. All rights reserved.

Key words: Proximal stomach; Stomach neoplasm; Laparoscopy; Lymph node excision; Splenic hilum

BRIEF ARTICLE

Pancreas- and spleen-preserving splenic hilum lymph node dissection in laparoscopic total gastrectomy is challenging. Even though a small number of skilled laparoscopic surgeons have demonstrated the safety and feasibility of this procedure, most surgeons adopt only the suprapancreatic approach. However, exposure and dissection of splenic hilum lymph nodes posterior to the splenic artery, especially its inferior branch is sometimes difficult and unpredicted injury or bleeding is more likely to occur if only through the suprapancreatic approach. We combined the supra- and infra-pancreatic approaches to better expose the posterior
splenic artery lymph nodes at the splenic hilum and dissect more safely.

Mou TY, Hu YF, Yu J, Liu H, Wang YN, Li GX. Laparoscopic splenic hilum lymph node dissection for advanced proximal gastric cancer: A modified approach for pancreas- and spleen-preserving total gastrectomy. World J Gastroenterol 2013; 19(30): 4992-4999 Available from: URL: http://www.wjgnet.com/1007-9327/full/v19/i30/4992.htm DOI: http://dx.doi.org/10.3748/wjg.v19.i30.4992

INTRODUCTION

The metastatic rate of splenic hilum lymph nodes (LNs) has been reported to range from 8% to 21% in advanced proximal gastric cancer\[1-6\], and the removal of splenic hilum LNs might bring about potential survival benefit for these patients. Accordingly, splenic hilum LN dissection is recommended in the surgical treatment for advanced proximal gastric cancer\[7\].

Traditionally, the dissection of splenic hilum LNs and nodes along the splenic artery (SA) is achieved through pancreatosplenectomy or pancreas-preserving splenectomy. However, it has been suggested that the combined resection of pancreas and/or spleen would significantly increase postoperative morbidity and mortality rather than improve prognosis, as well as decrease immunological function\[8-12\]. As an alternative, pancreas- and spleen-preserving splenic hilum LN dissection might decrease postoperative morbidity without compromising oncological principles\[13\].

With the rapid development of minimally invasive surgery, the application of laparoscopic surgery for gastric cancer is gradually gaining popularity\[14-16\]. However, due to the tortuous splenic vessels and possibility of parenchymal injury to the spleen or pancreas, it is still a challenging and technically demanding procedure for conducting laparoscopic pancreas- and spleen-preserving splenic hilum LN dissection. Only a few experienced laparoscopic surgeons have suggested its safety and feasibility\[17-19\], and most of them adopted the suprapancreatic approach to perform pancreas- and spleen-preserving splenic hilum LN dissection without using the infrapancreatic approach near pancreatic tail, while this method might not facilitate the dissection of LNs posterior to the splenic hilum.

Based on our anatomical understanding of peripancreatic fascia and spaces, we attempted a novel strategy combining supra- and infra-pancreatic approaches to perform laparoscopic pancreas- and spleen-preserving splenic hilum LN dissection in total gastrectomy for treating advanced proximal gastric cancer. Herein, detailed procedure and preliminary results are presented.

MATERIALS AND METHODS

Patients

Between August 2009 and August 2012, 112 patients with endoscopically biopsy-proven proximal gastric cancer underwent laparoscopic total gastrectomy in Nanfang Hospital, Southern Medical University. Among them, twelve consecutive patients underwent laparoscopic pancreas- and spleen-preserving splenic hilum LN dissection with curative intent.

Surgical indications

The indications for this procedure were as follows: (1) tumors were located at the upper- or middle-third of the stomach without distant metastasis; (2) tumors penetrated over the mucosa layer without invading adjacent structures; and (3) no gross involvement of the gastrosplenic ligament or LN number 4sh, at the splenic hilum or along the SA. Preoperative staging was confirmed by endoscopic ultrasound, abdominal high-resolution multidirectional computed tomography (CT), and positron emission computed tomography if necessary.

All surgical procedures were performed by Dr. Li GX, who had experience of over 500 laparoscopic gastrectomies for gastric cancer. All patients were given details about the operative procedure and potential risks before operation and provided written informed consent. This study was approved by the Ethics Committee of Nanfang Hospital.

Surgical procedures

The regional LNs were numbered according to the Japanese Classification of Gastric Carcinoma (JCGC) guidelines and LN dissection was done with laparoscopic ultrasonic shears [laparoscopic coagulation shears (LCSs); Ethicon Endo-Surgery, Cincinnati, OH, United States].

Under general anesthesia, the patient was placed in the supine position with legs set apart in a reverse Trendelenburg position. The surgeon stood on the patient’s left side, the assistant surgeon on the patient’s right side, and the camera operator stood between the patient’s legs. After pneumoperitoneum was established with CO₂ insufflated at a pressure of 12 mmHg, five working ports were introduced (Figure 1)\[20\]. Exploration of the abdominopelvic cavity was conducted to exclude distant metastasis and carcinomatosis.

The greater omentum was divided along the border of the transverse colon toward the inferior pole of the spleen. By dividing the gastrocolic ligament, the lesser sac was entered. The stomach was then overturned cephalad and the left gastroepiploic vessels were located at the boundary between the gastrocolic ligament and the gastrosplenic ligament, which were then divided at their roots (Figure 2A). By separating the gastrosplenic ligament up to the left side of the esophageal hiatus, the short gastric vessels were divided just adjacent to the spleen and the upper part of the greater curvature was mobilized. LN numbers 4sa and 2 were dissected. The right gastroepiploic vein was identified by tracing proximally along the gastrocolic trunk or dissecting the mesogastrium inferior to the gastric antrum off the transverse mesocolon, which was then ligated and divided at its origin. The right gastroepiploic artery was usually identified...
next to the vein, which was also divided to allow the removal of LN numbers 4d and 6 (Figure 2B). After overturning the gastric antrum cranially, the gastropancreatic fold was exposed. The gastroduodenal artery was usually located in the groove between the duodenum and pancreatic head, which was a clue to trace the celiac trunk and its branches. By following the common hepatic artery, the proper hepatic artery was traced. The right gastric artery was located in the hepatoduodenal ligament as a small branch running from the proper hepatic artery to the supra-pylorus. By ligating the right and left gastric arteries and veins at origin and dissecting the tissues around the proper hepatic artery, common hepatic artery and celiac trunk, the right side of the suprapancreatic LNs (numbers 5, 7, 8a, 9 and 12a) were removed en bloc (Figure 3).

By retracting the pancreas meticuiously in the caudal direction, the surgeon could dissect the soft tissue off the superior margin of the pancreatic body and tail in order to enter the retropancreatic space, thus uncovering the proximal SA (Figure 4A). From this step, in order to facilitate this manipulation, the surgeon changed his operating position and stood between the patient’s legs. By opening the artery sheath and skeletonizing the SA from the proximal portion towards the distal portion, LN number 11p could be removed. When the bifurcation was reached, two secondary branches of the SA could be seen in most cases. The superior branch coursed towards the superior pole of the spleen and the inferior one coursed directly towards the splenic hilum. The pancreatic tail was mobilized using the infrapancreatic approach to enter the retropancreatic space (Figure 4B). The superior and inferior branches of the SA were then skeletonized until they reached the splenic parenchyma (Figure 5). Meanwhile, the remaining short gastric vessels originating from the SA were further ligated and divided. By skeletonizing the SA, fatty tissues bearing LN numbers 10 and 11d were removed, and all vessels in the splenic hilum area were saved with the preservation of both the pancreas and the spleen.

The duodenum was transected 2 cm distal to the pylorus using an endoscopic linear stapler (Echelon 60 Endopath Stapler; Ethicon Endo-Surgery, Guaynabo, Puerto Rico, United States). Subsequently, the phrenoesophageal and both vagus nerves were divided, along with the removal of LN number 1. The transaction of the esophagus and Roux-en-Y esophageojunostomy were carried out extracorporeally through a 4-5 cm midline minilaparotomy just below the xiphoid process using a circular stapler. An end-to-side jejunojunostomy was performed by hand suture.

RESULTS
The clinicopathological characteristics of the patients are shown in Table 1. Surgical outcomes and postoperative
between 8% and 21%\(^1\) and was identified as an important prognostic factor for gastric carcinoma in previous studies.\(^4,6,9,21\) Splenic hilum LN involvement rate correlates with the depth of tumor invasion over the mucosal layer\(^2,3\), the tumor is classified as Bormann's type III or IV\(^13,5,22\), the tumor is located at the greater curvature\(^5\), and the tumor size is > 5 cm\(^4\). Thus, splenic hilum LN dissection should be conducted in patients with advanced proximal gastric cancer, especially those whose tumor has the above mentioned properties.

For the complete removal of splenic hilum LNs, in traditional open surgery, extended total gastrectomy including pancreatosplenectomy was once recommended as the classic procedure by some surgeons.\(^23,24\) However, combined resection of the distal pancreas is associated with increased postoperative complications, including acute pancreatitis, pancreatic fistula, abdominal abscess, and postoperative diabetes, which may even adversely affect survival. As a result, total gastrectomy with pancreas- and spleen-preserving splenectomy has been proposed by other surgeons.\(^11,25\) Other studies have demonstrated that splenectomy may result in higher morbidity and mortality, and has no significant survival benefit.\(^1,9,10,22,26\) Accordingly, pancreas- and spleen-preserving total gastrectomy has been attempted in open surgery\(^13\), although it is still controversial.

Laparoscopic gastrectomy, as an alternative to traditional open surgery for early gastric cancer, has been suggested to produce comparable morbidity and mortality, as well as long-term survival as open gastrectomy, while possessing the benefits of minimally invasive approaches.\(^27-32\) With respect to the above reasons, laparoscopic distal gastrectomy has gradually gained popularity for the treatment of early gastric cancer located in the lower portion of the stomach.\(^14,16,32\) However, only a few studies have reported the application of laparoscopic total gastrectomy in advanced proximal gastric cancer.\(^33-35\) With the development of laparoscopic devices and accumulation of experiences, a small number of skilled laparoscopic surgeons in high-volume specialized centers have attempted to extend the indications to advanced proximal gastric cancer using the strategy of splenic hilum LN dis-

**DISCUSSION**

Splenic hilum LN involvement was reported to range course are summarized in Tables 2 and 3. There were nine male and three female patients, with a mean age of 60.6 years (range, 45-75 years). The mean body mass index was 21.5 kg/m\(^2\) (range, 19.1-25.6 kg/m\(^2\)).

Laparoscopic total gastrectomy with pancreas- and spleen-preserving splenic hilum LN dissection was successfully performed in all 12 patients without conversion to open procedure. Only one patient experienced intraoperative bleeding during the skeletonization of the inferior branch of the SA. Pathological findings showed that tumor penetrated into the subserosal layer (T3) in only one patient and into the serosa without invasion to adjacent structures (T4a) in the other 11 patients. In accordance with the American Joint Committee on Cancer (AJCC) cancer staging manual, 7th edition, the TNM stages were distributed as follows: one stage II A, three stage II B, four stage III A, two stage III B, and two stage III C. The mean number of retrieved splenic hilum LNs per patient was 4.8 (range, 2-8) and only one patient had splenic hilum LN metastasis (8.3%). Postoperatively, neither morbidity nor mortality was observed (Table 3).

At a median follow-up of 21 mo (range, 1-37 mo), one patient had peritoneal metastasis after 12 mo of surgery and died 6 mo later. None of the other patients died or experienced recurrent disease during the follow-up period.

**Figure 4** Entering retropancreatic space. A: Near the superior margin of the pancreas (arrows); B: Near the lower margin of the pancreatic tail. a: Artery.

**Figure 5** Skeletonizing the branches of the splenic artery (arrows). a: Artery; v: Vein.
Table 1: Clinicopathological characteristics of patients

| Patient No. | Gender | Age (yr) | BMI (kg/m²) | Tumor location | Tumor size (cm) | Tumor depth¹ | TNM stage¹ | No. of retrieved splenic hilum LN² | No. of metastatic LN² | No. of metastatic splenic hilum LN² | Follow-up outcome |
|-------------|--------|----------|-------------|----------------|----------------|--------------|------------|-----------------------------------|---------------------|-------------------------------------|-------------------|
| 1           | Male   | 60       | 19.1        | U              | 5.0            | T4a          | III C      | 21                                | 7                   | 3                                   | No recurrence, alive |
| 2           | Male   | 73       | 24.8        | U              | 6.0            | T4a          | III B      | 18                                | 5                   | 4                                   | No recurrence, alive |
| 3           | Male   | 61       | 20.6        | U              | 8.5            | T4a          | II A       | 34                                | 2                   | 8                                   | No recurrence, alive |
| 4           | Male   | 62       | 20.2        | U              | 7.0            | T3           | II A       | 39                                | 0                   | 4                                   | No recurrence, alive |
| 5           | Male   | 59       | 20.8        | U              | 4.5            | T4a          | II B       | 16                                | 0                   | 3                                   | No recurrence, alive |
| 6           | Female | 54       | 20.4        | M              | 5.0            | T4a          | II A       | 20                                | 1                   | 5                                   | No recurrence, alive |
| 7           | Female | 57       | 24.0        | U              | 5.0            | T4a          | II A       | 20                                | 1                   | 7                                   | No recurrence, alive |
| 8           | Male   | 57       | 19.1        | U              | 8.0            | T4a          | III C      | 28                                | 21                  | 6                                   | No recurrence, alive |
| 9           | Male   | 61       | 25.6        | U              | 3.5            | T4a          | II A       | 16                                | 2                   | 4                                   | No recurrence, alive |
| 10          | Male   | 63       | 21.1        | M              | 2.9            | T4a          | II B       | 24                                | 0                   | 5                                   | No recurrence, alive |
| 11          | Female | 75       | 21.8        | U              | 5.5            | T4a          | III B      | 19                                | 3                   | 2                                   | No recurrence, alive |
| 12          | Male   | 45       | 20.6        | M              | 4.0            | T4a          | II B       | 35                                | 0                   | 6                                   | No recurrence, alive |

¹ “Tumor depth” and “Tumor node metastasis (TNM) stage” were in accordance with the AJCC cancer staging manual—7th edition; ² Lymph nodes (LN). BMI: Body mass index.

Table 2: Surgical outcomes, postoperative course and follow-up data of patients

| Patient No. | Operating time (min) | Estimated blood loss (mL) | Time to first flatus (POD) | Time to soft diet (POD) | Hospital stay (POD) | Follow-up (mo) | Follow-up outcome |
|-------------|----------------------|--------------------------|---------------------------|------------------------|-------------------|---------------|------------------|
| 1           | 230                  | 50                       | 5                         | 10                     | 10                | 37            | No recurrence, alive |
| 2           | 352                  | 300                      | 6                         | 10                     | 13                | 37            | No recurrence, alive |
| 3           | 180                  | 100                      | 4                         | 8                      | 11                | 36            | No recurrence, alive |
| 4           | 314                  | 100                      | 5                         | 7                      | 10                | 28            | No recurrence, alive |
| 5           | 278                  | 100                      | 4                         | 8                      | 12                | 24            | No recurrence, alive |
| 6           | 305                  | 100                      | 2                         | 9                      | 11                | 24            | No recurrence, alive |
| 7           | 298                  | 300                      | 5                         | 8                      | 12                | 24            | No recurrence, alive |
| 8           | 260                  | 150                      | 2                         | 4                      | 8                 | 18            | Peritoneal metastasis, death |
| 9           | 280                  | 200                      | 3                         | 5                      | 6                 | 6             | No recurrence, alive |
| 10          | 233                  | 50                       | 2                         | 6                      | 7                 | 5             | No recurrence, alive |
| 11          | 221                  | 150                      | 3                         | 4                      | 5                 | 4             | No recurrence, alive |
| 12          | 242                  | 200                      | 3                         | 7                      | 8                 | 1             | No recurrence, alive |

POD: Postoperative days.

Table 3: Surgical outcomes and postoperative courses of laparoscopic pancreas- and spleen-preserving splenic hilum lymph nodes dissection

| Items                        | mean ± SD (range) |
|------------------------------|-------------------|
| Operating time (min)         | 268.4 ± 48.0 (180-352) |
| Estimated blood loss (mL)    | 150.0 ± 85.3 (50-300) |
| No. of retrieved LN          | 242 ± 7.9 (16-39) |
| No. of metastatic LN         | 3.5 ± 5.9 (0-21) |
| No. of retrieved splenic hilum LN | 4.8 ± 1.8 (2-8) |
| No. of metastatic splenic hilum LN | 0.3 ± 0.9 (0-3) |
| Time to first flatus (POD)   | 3.7 ± 1.4 (2-6) |
| Time to soft diet (POD)      | 7.2 ± 2.1 (4-10) |
| Hospital stay (POD)          | 9.4 ± 2.6 (5-13) |
| Intraoperative complication  | 1 (8.3%)          |
| Postoperative complication   | 0                 |
| Mortality                    | 0                 |

LN: Lymph nodes; POD: Postoperative days.

The major difficulties of this laparoscopic procedure lie in the complicated variations of the SA supplying the spleen with its variable branching. The greatest challenges to surgeons are the high probability of injuries to the splenic vessels, unpredicted avulsion of the splenic capsule, skillful manipulation of endoscopic devices in a limited space, and injuries to the splenic hilum during skeletonization of the splenic vessels. Our strategy to deal with these difficulties was based on our thorough understanding of anatomy under laparoscopic view, and team cooperation. The SA is located in the retropancreatic space, coursing near the superior margin of the pancreas and usually dividing into two terminal branches near the pancreatic tail. The inferior branch of the SA courses directly into the splenic hilum, therefore, the exposure and dissection was continued leftward only through the suprapancreatic approach, bleeding and unpredicted injury were more likely to occur due to the exposure limit. Thus, in our clinical practice, the suprapancreatic approach was adopted for the skeletonization of the SA trunk, its superior branch, and the upper hemisphere of its inferior branch. Then, the lower margin of the pancreatic tail was mobilized. Since the retropancreatic space was filled with loose
Our strategy for laparoscopic pancreas- and spleen-preserving splenic hilum LN dissection is different from that in previous reports in the literature. The hand-assisted technique was adopted by Uyama et al.,[17] taping the SA was applied by Hur et al.[18], and Hyung stood at the patient’s right side and skeletonized the distal portion of the SA as soon as completing division of the gastro-splenic ligament[19]. To our knowledge, all these surgeons adopted the suprapancreatic approach. However, one similarity we noted was that when approaching the splenic hilum, meticulous manipulation was required to avoid injury. In Hyung’s report, preoperative assessment of the splenic vascular anatomy was conducted with CT in collaboration with radiologists.[18] In our study, we experienced an episode of major intraoperative bleeding during dissection of the inferior branch of the SA in one of our patients. We applied endoscopic gauze to compress the bleeding area and identified the bleeding point. A hemo-lock was then used to clip onto the artery surface, involving the bleeding point without fully clamping the whole artery. Successfully, the bleeding was finally controlled after some maneuvers. In retrospect, even if this attempt was not successful, splenectomy could be safely conducted because the splenic pedicle was freed. Given these aspects, the average operating time was increased to 268.4 min, and the time was especially longer for the first three cases; nevertheless, our average operating time was still in congruent with that in the previous reports.[17-19]. Although the patients in our study suffered from a more advanced stage of gastric carcinoma, the early follow-up results showed satisfactory survival.

In our study, only one out of 12 patients had splenic hilum LN metastasis. Interestingly, this patient had an overall high percentage of positive LNs, experienced peritoneal metastasis at 12 mo after surgery and died 6 mo later. This finding might suggest that splenic hilum LN involvement is always associated with highly advanced proximal gastric cancers, and poorer prognosis in these patients might be predicted. Similarly, Shin et al.[20] found that splenic hilum LN metastasis had a poor prognosis. However, due to the limitation of our relatively small sample size, the correlation between splenic hilum LN metastasis and oncological outcomes needs to be further confirmed.

Our retrospective study also had several limitations, including patient selection bias and relatively small sample size. However, to the best of our knowledge, this is a modified approach for conducting laparoscopic pancreas- and spleen-preserving splenic hilum LN dissection. The detailed procedure might be useful for surgeons who wish to conduct similar laparoscopic surgery.

In conclusion, using the strategy of combining supra- and infra-pancreatic approach to extend the retropancreatic space in experienced hands, laparoscopic total gastrectomy with pancreas- and spleen-preserving splenic hilum lymph nodes dissection for the treatment of advanced proximal gastric cancer in selected patients could be safe and feasible. However, long-term follow-up and randomized clinical trials to evaluate its surgical safety and oncological efficacy are needed.

ACKNOWLEDGMENTS

The authors thank Dr. Wat Yiu-Kin Jason from Queen Elizabeth Hospital, Hong Kong for his assistance in the English writing of the manuscript.

COMMENTS

Background

Laparoscopic gastrectomy, as a minimally invasive alternative treatment to traditional open surgery in treating gastric cancer, is gaining popularity worldwide. For advanced gastric cancer, radical surgery should accomplish adequate lymph node (LN) dissection (D2 lymphadenectomy) according to oncological principles. Splenic hilum LN dissection should be included in the D2 lymphadenectomy when treating advanced proximal gastric cancer.

Research frontiers

Traditional removal of splenic hilum LNs was achieved through combined resection of the pancreas and spleen. However, it has been suggested that combined resection would increase postoperative morbidity and mortality and not significantly benefit patient survival. Thus, pancreas- and spleen-preserving total gastrectomy was subsequently attempted in open and laparoscopic surgery.

Innovations and breakthroughs

In laparoscopic total gastrectomy, pancreas- and spleen-preserving splenic hilum LN dissection is challenging because of the tortuous splenic vessels and possibility of parenchymal injury to the spleen or pancreas. To date, only a small number of skilled laparoscopic surgeons in high-volume specialized centers can achieve splenic hilum LN dissection in pancreas- and spleen-preserving total gastrectomy, and most of them only adopt the suprapancreatic approach. This method might not facilitate the dissection of LNs posterior to the splenic hilum and might cause unpredicted injury to splenic vessels. Thus, they modified this strategy by combining both supra- and infra-pancreatic approaches to better expose the posterior splenic artery LNs at the splenic hilum, and dissect more safely.

Applications

Using the strategy of combining supra- and infra-pancreatic approach to extend the retropancreatic space in experienced hands, laparoscopic total gastrectomy with pancreas- and spleen-preserving splenic hilum lymph nodes dissection for the treatment of advanced proximal gastric cancer in selected patients could be safe and feasible. The indications for laparoscopic surgery could be extended to advanced proximal gastric cancer. The detailed procedure described here might be useful for laparoscopic surgeons. However, due to the limited sample size, further long-term follow-up results and randomized controlled trials are needed to ascertain its surgical safety and oncological efficacy.

Terminology

In advanced gastric cancer, the tumor penetrates the mucosal layer of the stomach wall. In advanced proximal gastric cancer, the tumor is located in the upper or middle third of the stomach. Splenic hilum LNs are the LNs located adjacent to the splenic artery distal to the pancreatic tail, those on the roots of the short gastric arteries, and those along the left gastroepiploic artery proximal to its first gastric branch, according to the Japanese Classification of Gastric Carcinoma guidelines.
**REFERENCES**

1. Maehara Y, Moriguchi S, Yoshida M, Takahashi I, Korenaga D, Sugimachi K. Splenectomy does not correlate with length of survival in patients undergoing curative total gastrectomy, for gastric carcinoma. Univariate and multivariate analyses. *Cancer* 1991; 67: 3006-3009 [PMID: 2044047]

2. Kitamura K, Nishida S, Yamamoto K, Ichikawa D, Okamoto T, Taniguchi H, Yamaguchi T, Sawai K, Takahashi T. Lymph node metastasis in gastric cancer in the upper third of the stomach--surgical treatment on the basis of the anatomical distribution of positive node. *Hepatogastroenterology* 1998; 45: 281-285 [PMID: 9496227]

3. Ikeguchi M, Kaibara N. Lymph node metastasis at the splenic hilum in proximal gastric cancer. *Ann Surg 2004; 70*: 645-648 [PMID: 15279911]

4. Shin SH, Jung H, Choi SH, An JY, Choi MG, Noh JH, Sohn TS, Bae JM, Kim W. Clinical significance of splenic hilar lymph node metastasis in proximal gastric cancer. *Ann Surg Oncol* 2009; 16: 1304-1309 [PMID: 19241107 DOI: 10.1245/s10434-008-0827-y]

5. Kosuga T, Ichikawa D, Okamoto K, Komatsu S, Shiozaki A, Fujiwara H, Otsuji E. Survival benefits from splenic hilar lymph node dissection by splenectomy in gastric cancer patients: relative comparison of the benefits in subgroups of patients. *Gastric Cancer* 2011; 14: 172-177 [PMID: 21331530 DOI: 10.1007/s10120-011-0028-2]

6. Nashimoto A, Yabushaki H, Matsumi A. The significance of splenectomy for advanced proximal gastric cancer. *Int J Surg Oncol 2012; 2012*: 301530 [PMID: 22685639 DOI: 10.1155/2012/301530]

7. **Japanese Gastric Cancer Association.** Japanese gastric cancer treatment guidelines 2010 (ver. 3). *Gastric Cancer 2011; 14*: 113-123 [PMID: 21573742 DOI: 10.1016/j.igca.2011-0024-2]

8. Cuschieri A, Weeden S, Fielding J, Banczewicz J, Craven J, Joypaal V, Sydes M, Fayers P. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC future treatment strategy. *Surg Endosc* 2012; 26: 1173-1177 [PMID: 12846008]

9. Mönig SP, Collet PH, Balduis SE, Schmackpfeffer K, Schröder W, Thiele J, Dienes HP, Hölscher AH. Splenectomy in proximal gastric cancer: frequency of lymph node metastasis to the splenic hilus. *J Surg Oncol* 2001; 76: 89-92 [PMID: 11223832]

10. Shiu MH, Papaczristou DN, Kosloff C, Eliopoulos G. Selection of operative procedure for adenocarcinoma of the stomach. Twenty years’ experience with implications for future treatment strategy. *Ann Surg 1980; 192*: 730-737 [PMID: 7447526 DOI: 10.1097/00000658-198012000-00007]

11. Maruyama K, Gunev P, Okabayashi K, Sasaki M, Kinoshita T. Lymph node metastases of gastric cancer. General pattern in 1931 patients. *Ann Surg 1989; 210*: 569-562 [PMID: 2818028 DOI: 10.1097/00000658-198911000-00005]

12. Maruyama K, Sasaki M, Kinoshita T, Sano T, Kati H, Ojima K. Pancreas-preserving total gastrectomy for gastric cancer. *World J Surg 1995; 19*: 532-536 [PMID: 7676665 DOI: 10.1007/BF0103917]

13. Lee KY, Noh SH, Hyung WJ, Lee JH, Lah KH, Choi SH, Min JS. Impact of splenectomy for lymph node dissection on long-term surgical outcome in gastric cancer. *Ann Surg Oncol 2001; 8*: 402-406 [PMID: 11407513 DOI: 10.1023/A:10103436-01400-02]

14. Kim YW, Bae YH, Yun YH, Nam BH, Kim DH, Choi IJ, Bae JH. Improved quality of life outcomes after laparoscopic-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. *Ann Surg 2008; 248*: 721-727 [PMID: 18948798 DOI: 10.1097/SLA.0b013e31817ba810]

15. Uyama Y, Gugia K, Sakurai Y, Komori Y, Harai T, Matsu H, Fujita J, Nakamura Y, Ochiai M, Hasumi A. Hand-assisted laparoscopic function-preserving and radical gastrectomies for advanced-stage proximal gastric cancer. *J Am Coll Surg 2004; 199*: 508-515 [PMID: 15325625 DOI: 10.1016/j.jamcollsurv.2004.04.020]

16. Hyung WJ, Lim JS, Song JI, Choi SH, Noh SH. Japanese splenectomy-preserving splenic hilar lymph node dissection during total gastrectomy for gastric cancer. *J Am Coll Surg 2008; 207*: e6-11 [PMID: 18668040 DOI: 10.1016/j.jamcollsurg.2008.04.027]

17. Furukawa H, Hiratsuka M, Ishikawa O, Ikeda M, Imamura H, Maruyama K, Taniguchi H, Yamaguchi T, Sawai K, Takahashi T. Lymph node metastasis in proximal gastric cancer. *Surg Endosc* 2002; 79: 73-76 [PMID: 11754382 DOI: 10.1002/seo.10036]

18. Kitano S, Ito Y, Moriyama M, Sugimachi K. Laparoscopic-assisted Billroth I gastrectomy. *Surg Laparosc Endosc Endogr Surg 1994; 4*: 146-148 [PMID: 818078]

19. Song KY, Kim SN, Park CH. Laparoscopic-assisted distal gastrectomy with D2 lymph node dissection for gastric cancer: technical and oncologic aspects. *Surg Endosc 2008; 22*: 655-659 [PMID: 17593447 DOI: 10.1007/s00464-007-9431-5]

20. Kawamura H, Homma S, Yokota R, Yokota K, Watarai H, Hagiwara M, Sato M, Noguchi K, Ueki S, Kondo Y. Inspection of safety and accuracy of D2 lymph node dissection in laparoscopic-assisted distal gastrectomy. *World J Surg 2008; 32*: 2366-2370 [PMID: 18668280 DOI: 10.1007/s00268-008-9697-3]
Kitano S, Shiraishi N, Fujii K, Yasuda K, Inomata M, Adachi Y. A randomized controlled trial comparing open vs laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer: an interim report. *Surgery* 2002; 131: S30e-S311 [PMID: 11821829 DOI: 10.1067/msy.2002.120115]

Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, Ryu SW, Lee HJ, Song KY. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report—a phase III multicenter, prospective, randomized Trial (KCLASS Trial). *Ann Surg* 2010; 251: 417-420 [PMID: 20160637 DOI: 10.1097/SLA.0b013e3181cc8f6b]

Liang Y, Li G, Chen P, Yu J, Zhang C. Laparoscopic versus open gastrectomy for early distal gastric cancer: a meta-analysis. *ANZ J Surg* 2011; 81: 673-680 [PMID: 2295306 DOI: 10.1111/j.1445-2197.2010.05599.x]

Uyama I, Sugioka A, Fujita J, Komori Y, Matsu H, Hasumi A. Laparoscopic total gastrectomy with distal pancreatopancreaticoduodenectomy and D2 lymphadenectomy for advanced gastric cancer. *Gastric Cancer* 1999; 2: 220-224 [PMID: 11957104 DOI: 10.1007/s101200050869]

Mochiki E, Toyomasu Y, Ogata K, Andoh H, Ohno T, Aihara R, Asao T, Kuvano H. Laparoscopically assisted total gastrectomy with lymph node dissection for upper and middle gastric cancer. *Surg Endosc* 2008; 22: 1997-2002 [PMID: 18594925 DOI: 10.1007/s00464-008-0015-9]

Lee JH, Ahn SH, Park do J, Kim HH, Lee HJ, Yang HK. Laparoscopic total gastrectomy with D2 lymphadenectomy for advanced gastric cancer. *World J Surg* 2012; 36: 2394-2399 [PMID: 22674092 DOI: 10.1007/s00268-012-1669-y]

Sakuramoto S, Kikuchi S, Futawatari N, Katada N, Moriya H, Hirai K, Yamashita K, Watanabe M. Laparoscopy-assisted pancreas- and spleen-preserving total gastrectomy for gastric cancer as compared with open total gastrectomy. *Surg Endosc* 2009; 23: 2416-2423 [PMID: 19266232 DOI: 10.1007/s00464-009-0371-0]

Jáuregui E. [Anatomy of the splenic artery]. *Rev Fac Cien Med Univ Nac Cordoba* 1999; 56: 21-41 [PMID: 10668264]

Pandey SK, Bhattacharya S, Mishra RN, Shukla VK. Anatomical variations of the splenic artery and its clinical implications. *Clin Anat* 2004; 17: 497-502 [PMID: 15300870 DOI: 10.1002/ca.10220]

Madoff DC, Denys A, Wallace MJ, Murthy R, Gupta S, Pillsbury EP, Ahrar K, Bessoud B, Hicks ME. Splenic arterial interventions: anatomy, indications, technical considerations, and potential complications. *Radiographics* 2005; 25 Suppl 1: S191-S211 [PMID: 16227491 DOI: 10.1148/rg.25si055504]

Zhang C, Yu J, Wang YN, Hu YF, Li GX. [Living anatomical observations on peripancreatic spaces and their implications on laparoscopic gastrectomy with D(2) lymphadenectomy for distal gastric cancer]. *Zhonghua Weichang Waike Zazhi* 2009; 12: 117-120 [PMID: 19296242]

P- Reviewers: Nunobe S, Wei HB  S- Editor: Wen LL  L- Editor A  E- Editor: Zhang DN
